AHA 2025 Clinical Insights: Advancing Cardiology Care
Explore concise, expert-led educational activities delivering the latest updates from AHA 2025. Dive into key developments across atrial fibrillation, heart failure, lipid management, and aortic stenosis. Find out how breakthrough science is translating into practical clinical impact.
1-10 of 10

Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CEEarlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE

Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
CardiologyAdvancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial

The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
CardiologyThe Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks

Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
CardiologySotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025

The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options

The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
- advertisement

Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
CardiologyPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke

Real-World Impact of Evolocumab on MACE Reduction in ASCVD
CardiologyReal-World Impact of Evolocumab on MACE Reduction in ASCVD

Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
CardiologyGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study

Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
CardiologyEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
- advertisement



























